NeuroOne Medical Technologies C
NMTC
Positions held
Your positionsNMTC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $9.83M | Enterprise value | $7.96M | Trailing P/E | — | Forward P/E | -3.86 |
| PEG | — | Price / book | 2.49 | Beta | 0.76 | Dividend yield | 0.00% |
| Revenue growth | 16.3% | Earnings growth | — | Gross margin | 23.0% | Operating margin | -122.9% |
| Profit margin | -59.7% | ROE | -124.7% | ROA | -58.1% | Debt / equity | 0.05 |
| Current ratio | 2.84 | Free cash flow | -$4.57M | Analyst recommendation | strong_buy | Mean target | $7.27 |
| 52w high | $6.42 | 52w low | $0.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $1.9M | $2.9M | $2.7M | $1.7M | — |
| Op margin | -122.9% | -128.7% | -59.0% | -50.0% | -111.2% | — |
| Net income | -$2.0M | -$2.4M | -$1.4M | -$1.6M | -$1.5M | — |
| Gross margin | 59.9% | 53.2% | 54.2% | 55.8% | 53.9% | — |
| Gross profit | $1.2M | $1.0M | $1.6M | $1.5M | $0.9M | — |
| Operating income | -$2.4M | -$2.4M | -$1.7M | -$1.4M | -$1.9M | — |
- Revenue +6% vs prior quarter ($2.0M vs $1.9M).
- Gross margin 59.9% (was 53.2% prior quarter).
- Operating margin expanded to -122.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $9.1M | $3.5M | $2.0M | $0.2M |
| Op margin | -46.5% | -344.3% | -612.3% | -5860.2% |
| Net income | -$3.6M | -$12.3M | -$11.9M | -$10.0M |
| Gross margin | 56.5% | 31.3% | 23.4% | -41.4% |
| Gross profit | $5.1M | $1.1M | $0.5M | -$0.1M |
| Operating income | -$4.2M | -$11.9M | -$12.0M | -$10.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
2026-10-05 · NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
2026-08-27 · NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform
2026-08-20 · NeuroOne (NMTC) Q3 2026 Earnings Call Transcript
2026-08-17 · NeuroOne Medical Technologies Corp (NMTC) (Q3 2026) Earnings Call Highlights: Revenue Grows 16% ...
2026-08-14 · NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary
2026-08-11 · NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification
Price (daily)
Full chart · RSI · MACD · patterns